Acadia Pharma (ACAD) Tops Q3 EPS by 5c, Beats on Revenue, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
November 2, 2023 4:05 PM EDT- Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise
- 3Q23 DAYBUE (trofinetide) net product sales of $66.9 million
- 3Q23 NUPLAZID® (pimavanserin) net product sales of $144.8 million
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023.
In the third quarter, Acadia delivered record product revenue, underscoring the continued strong launch of DAYBUE for the treatment of Rett syndrome, and market share growth for the... More
